PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, in collaboration with its FDA testing contractors and development team, met with the FDA to discuss the Company’s regulatory path. The Company believes that its product, PHER-O2, is appropriately suited for whole organ (pancreas and kidney), preservation for transplantation.
